Compare LEGN & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEGN | OBDC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.5B |
| IPO Year | 2020 | 2019 |
| Metric | LEGN | OBDC |
|---|---|---|
| Price | $20.53 | $12.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $68.67 | $14.44 |
| AVG Volume (30 Days) | 2.3M | ★ 4.2M |
| Earning Date | 03-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 12.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.39 |
| Revenue | $909,045,000.00 | ★ $1,797,946,000.00 |
| Revenue This Year | $68.20 | $19.12 |
| Revenue Next Year | $47.77 | N/A |
| P/E Ratio | ★ N/A | $8.93 |
| Revenue Growth | ★ 74.75 | 11.43 |
| 52 Week Low | $20.21 | $11.65 |
| 52 Week High | $45.30 | $15.73 |
| Indicator | LEGN | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 50.00 |
| Support Level | $20.21 | $12.31 |
| Resistance Level | $23.88 | $12.78 |
| Average True Range (ATR) | 1.32 | 0.26 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 21.29 | 77.50 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.